This is The First Diabetes Drug to Reduce Cardiovascular Events in At-Risk People
A new large-scale study reveals that Eli Lilly's diabetes drug Jardiance is the first to significantly lower cardiovascular (CV) risk factors in people with type 2 diabetes.
The drug, according to a press release on the study, is the only blood sugar-lowering agent that has shown CV risk reduction in type-2 diabetics who have a greater risk for events like heart attack or stroke.
-
Sell Your Test Strips for Cash
Sell Your Test Strips With Confidence. We Offer Top Prices, Free Shipping, Fast Payments.
www.assistdiabetics.com
See It Now -
We Buy Your Unused Test Strips
Do You Have Unused Diabetes Test Strips? Get Cash Fast For Your Test Strips. Earn Money Today.
www.assistdiabetics.com/sell/test/strips
See It Now
“Approximately 50 percent of deaths in people with type 2 diabetes worldwide are caused by cardiovascular disease," said Professor Hans-Juergen Woerle of the Boehringer Ingelheim. "Reducing cardiovascular risk is an essential component of diabetes management."
More detailed results to come
The study included more than 7,000 people from 42 countries who were observed for an average of 3 years.
Jardiance's safety profile was shown to be consistent with other studies that have been conducted on the drug. First approved in August of this year, Jardiance lowers overall blood glucose levels by blocking the SGLT2 protein.
More detailed results about the study will be presented in September at the European Association for the Study of Diabetes Annual Meeting in Sweden.
Source: BusinessWire, International Business Times
Image courtesy of nuchylee/FreeDigitalPhotos.net
Get a Free Diabetes Meal Plan
Get a free 7-Day Diabetes Meal Plan from Constance Brown-Riggs who is a Registered Dietitian-Certified Diabetes Educator and who is also a national spokesperson for the American Dietetic Association.
Just enter in your email below to download your free Diabetes Meal Plan.